Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...

The chief executive of a prominent crypto analytics firm believes that the Bitcoin (BTC) bull market is far from over despite a correction to the $78,000 level. CryptoQuant CEO ... the end of the ...